David T Weaver Selected Research

Therapeutics

1/2023	Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.
1/2023	Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib.
10/2019	DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
1/2019	Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
1/2016	Synergism of FAK and tyrosine kinase inhibition in Ph+ B-ALL.
9/2012	Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
8/2011	XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.
10/2005	Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors.
2/2005	Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David T Weaver Research Topics

Disease

15	Neoplasms (Cancer) 01/2023 - 12/2010
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2023 - 10/2019
3	Disease Progression 01/2020 - 01/2019
3	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2017
3	Breast Neoplasms (Breast Cancer) 08/2017 - 01/2011
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2023 - 10/2019
2	Leukemia 01/2023 - 01/2020
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020 - 01/2017
2	Malignant Mesothelioma 01/2019 - 05/2014
2	Triple Negative Breast Neoplasms 08/2017 - 12/2010
2	Adenocarcinoma 01/2017 - 01/2016
2	Squamous Cell Carcinoma of Head and Neck 01/2014 - 08/2011
2	Hemorrhage 10/2005 - 02/2005
1	Lymphocytosis 01/2023
1	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2023
1	Fatigue 01/2020
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020
1	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 10/2019
1	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 10/2019
1	Mesothelioma 01/2019
1	Ovarian Neoplasms (Ovarian Cancer) 01/2019
1	Diarrhea 12/2018
1	Hematologic Neoplasms (Hematological Malignancy) 12/2018
1	Fever (Fevers) 12/2018
1	Nausea 12/2018
1	Anemia 12/2018
1	Cough 12/2018
1	Neutropenia 12/2018
1	Myeloid Leukemia (Leukemia, Myelocytic) 01/2017
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2016
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2016
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2015
1	Neurofibromatosis 2 (Neurofibromatosis Type II) 05/2014
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2014
1	Pathologic Complete Response 05/2012
1	Esophageal Neoplasms (Esophageal Cancer) 05/2012
1	Thrombosis (Thrombus) 02/2005
1	Genomic Instability 01/2004
1	Ataxia Telangiectasia (Louis Bar Syndrome) 12/2002

Drug/Important Bio-Agent (IBA)

7	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2020 - 05/2014
6	Biomarkers (Surrogate Marker)IBA 01/2014 - 12/2010
5	duvelisibIBA 01/2023 - 12/2018
5	PND 1186IBA 01/2020 - 05/2014
5	Proteins (Proteins, Gene)FDA Link 01/2017 - 12/2010
3	defactinibIBA 01/2020 - 08/2017
3	PlatinumIBA 01/2019 - 08/2011
3	Phosphotransferases (Kinase)IBA 08/2017 - 12/2002
3	Formaldehyde (Formol)FDA Link 09/2012 - 01/2011
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2023 - 12/2018
2	ofatumumab FDA Link 01/2020 - 12/2018
2	Aldehyde DehydrogenaseIBA 01/2019 - 05/2014
2	Neurofibromin 2 (Merlin)IBA 01/2019 - 05/2014
2	CateninsIBA 01/2019 - 07/2018
2	ParaffinIBA 09/2012 - 05/2012
2	DNA (Deoxyribonucleic Acid)IBA 08/2011 - 01/2004
1	Agammaglobulinaemia Tyrosine KinaseIBA 01/2023
1	ibrutinibIBA 01/2023
1	Protein Isoforms (Isoforms)IBA 01/2023
1	BilirubinIBA 01/2020
1	venetoclaxIBA 01/2020
1	Rituximab (Mabthera)FDA Link 10/2019
1	Tyrosine (L-Tyrosine)FDA Link 01/2019
1	Deubiquitinating EnzymesIBA 07/2018
1	P-2 (P 2)IBA 01/2017
1	130-nm albumin-bound paclitaxelIBA 01/2017
1	Gemcitabine FDA Link 01/2017
1	Collagen Type I (Type I Collagen)IBA 01/2017
1	Small Interfering RNA (siRNA)IBA 01/2017
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2015
1	VS-5584IBA 01/2015
1	Cisplatin (Platino)FDA LinkGeneric 01/2015
1	AsbestosIBA 05/2014
1	MAP-kinase-activated kinase 2IBA 01/2014
1	P 11 (P-11)IBA 09/2012
1	Methotrexate (Mexate)FDA LinkGeneric 09/2012
1	Keratins (Keratin)IBA 09/2012
1	AnthracyclinesIBA 09/2012
1	A-Form DNA (A-DNA)IBA 09/2012
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2011
1	Progesterone Receptors (Progesterone Receptor)IBA 12/2010
1	Estrogen ReceptorsIBA 12/2010
1	AntibodiesIBA 12/2010
1	CoagulantsIBA 02/2005
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 02/2005
1	Warfarin (Coumadin)FDA LinkGeneric 02/2005

Therapy/Procedure

9	Therapeutics 01/2023 - 02/2005
9	Drug Therapy (Chemotherapy) 10/2019 - 08/2011
1	Radioimmunotherapy 10/2019
1	Adjuvant Chemotherapy 01/2019
1	Oral Administration 08/2017
1	Immunotherapy 01/2016
1	Induction Chemotherapy 01/2014
1	Chemoradiotherapy 01/2014
1	Palliative Care (Palliative Therapy) 09/2012
1	Neoadjuvant Therapy 05/2012
1	Radiotherapy 08/2011